Annovis Bio (NYSE: ANVS) plans to deliver three presentations at the 19th Clinical Trials on Alzheimer’s Disease (CTAD) conference, scheduled for Nov. 16-19, 2026, in Boston, the Malvern, Pennsylvania-based company announced. The presentations will center on buntanetap, its investigational once-daily oral therapy for neurodegenerative disease, and come as the company approaches a pivotal clinical data readout in early 2027 while preparing a New Drug Application.
The timing gives the conference appearances added weight. Alzheimer’s disease remains one of medicine’s most stubborn targets, and an oral therapy designed to act on the underlying causes of neurodegeneration rather than only on symptoms would represent a meaningful shift in how the disease is treated. For investors, the CTAD program offers an early, public look at the science behind a trial whose results are expected to define the company’s near-term future.
The presentations cover three distinct areas. One will address buntanetap’s mechanism of action targeting neurotoxic proteins. Another will detail the design and baseline characteristics of the company’s pivotal Phase 3 study in early Alzheimer’s disease. A third will examine the use of artificial intelligence to predict blood-brain barrier permeability of late-stage Alzheimer’s drug candidates, a question of central importance for any therapy that must reach the brain to work.
The program includes an oral presentation on Nov. 19 by Alexander Morin, director of strategic communications, and two poster presentations scheduled for Nov. 16-17, including one by Chief Scientific Officer Cheng Fang. The full press release is available at https://nnw.fm/2k4SQ, and additional information about the company can be found at www.annovisbio.com.
Buntanetap, formerly known as posiphen, is described as inhibiting the translation of multiple neurotoxic proteins, including APP and amyloid beta, tau, alpha-synuclein and TDP-43, through a specific RNA-targeting mechanism. By addressing multiple proteins implicated in neurodegeneration simultaneously, the approach differs from therapies aimed at a single target, a distinction the company says is central to its effort to halt disease progression and improve cognitive and motor function in patients.
Annovis is a Phase 3 clinical-stage biotechnology company developing treatments for Alzheimer’s and Parkinson’s disease. The company maintains a presence on LinkedIn, YouTube and X, and the latest news and updates relating to the stock are available in its newsroom at https://nnw.fm/ANVS.
The announcement was distributed through NetworkNewsWire, part of the Dynamic Brand Portfolio at IBN, which provides wire solutions through InvestorWire along with editorial syndication to 5,000+ outlets and social media distribution. Terms of use and disclaimers for the content are posted at https://www.NetworkNewsWire.com/Disclaimer.
